Monopar Therapeutics (NASDAQ:MNPR) Now Covered by Lake Street Capital

Key Points

• Monopar Therapeutics has been upgraded to a "strong-buy" rating by Lake Street Capital, indicating a positive outlook from analysts.
• The stock has a twelve month high of $74.00 and a market cap of approximately $450.66 million.
• Insider transactions include significant sales by directors, with a total of 42,504 shares sold over the last 90 days.

Research analysts at Lake Street Capital assumed coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The brokerage set a "buy" rating and a $106.00 price target on the stock. Lake Street Capital's price objective would suggest a potential upside of 45.13% from the company's previous close.

A number of other analysts have also issued reports on the company. Chardan Capital reissued a "buy" rating and issued a $60.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, September 16th. HC Wainwright started coverage on shares of Monopar Therapeutics in a research note on Tuesday, August 26th. They issued a "buy" rating and a $70.00 price target for the company. Oppenheimer started coverage on shares of Monopar Therapeutics in a research note on Wednesday, September 3rd. They issued an "outperform" rating and a $77.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating and issued a $74.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, August 27th. Finally, Raymond James Financial started coverage on shares of Monopar Therapeutics in a research note on Tuesday, September 2nd. They issued a "strong-buy" rating and a $80.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $80.22.

Monopar Therapeutics Stock Up 7.9%

Shares of NASDAQ MNPR opened at $73.04 on Tuesday. The firm has a market cap of $450.66 million, a price-to-earnings ratio of -21.93 and a beta of 1.20. Monopar Therapeutics has a 52-week low of $4.12 and a 52-week high of $74.00. The business's 50 day moving average is $43.25 and its two-hundred day moving average is $38.70.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.12. Analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Christopher M. Starr sold 16,800 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the director owned 5,173 shares in the company, valued at approximately $206,920. The trade was a 76.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the business's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the transaction, the director owned 11,486 shares of the company's stock, valued at approximately $459,440. The trade was a 43.67% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,504 shares of company stock worth $1,700,160. Corporate insiders own 20.50% of the company's stock.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey acquired a new position in Monopar Therapeutics in the second quarter valued at $34,000. AlphaQuest LLC acquired a new position in Monopar Therapeutics in the first quarter valued at $44,000. JPMorgan Chase & Co. boosted its stake in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after acquiring an additional 1,821 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Monopar Therapeutics in the second quarter valued at $80,000. Finally, New York State Common Retirement Fund acquired a new position in Monopar Therapeutics in the second quarter valued at $104,000. Institutional investors and hedge funds own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.